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Abstract
Objective:  To  compare  the  effects  of  intravenous  hyoscine  butylbromide  versus  placebo  on  the
duration of  labor  in term  pregnancies.
Materials  and  methods:  86  patients  were  selected  and  randomly  assigned  to  receive  intra-
venous  hyoscine  butylbromide  (20  mg  twice)  (n  =  43)  or  an  intravenous  placebo  (saline  solution
10 cc)  (n  = 43).  We  evaluated  maternal  adverse  effects,  effects  on  neonatal  Apgar  score,  cer-
vical dilatation  1  h  after  drug  administration  and  the interval  between  the  onset  of  labor  and
delivery.
Results: No significant  differences  were  observed  in  the  duration  of phases  of  labor  between
the two  groups.  No significant  differences  were  found  between  the  groups  in Apgar  scores  at  1
and 5 min.  No  maternal  adverse  effects  were  observed  or  reported  due  to  the  use  of  hyoscine
butylbromide  or  the  placebo.  On the first  phase  of  primigravidas  it  shortens  the  first  labor  phase
up to  159.1  ±  84  min  vs.  the  control  group  (p  = 0.002).
Conclusion:  Hyoscine  butylbromide  oxytocin  shortens  the  duration  of  labor  in  term  primigravida
pregnancies. No  side effects  were  reported.
© 2014  Universidad  Autónoma  de  Nuevo  León.  Published  by  Masson  Doyma  México  S.A.  All  rights
reserved.
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Introduction
Labor  is  a  sequential  physiological  event.  It  integrates
changes  that  will  take  place  in the  myometrium,  decidua
and  cervix,  which  occur  over  a  period  of  days,  or  even
weeks.  Biochemical  changes  appear  before  the  onset  of
uterine  contractions  and  cervical  dilatation.1 Labor  at term,
supposes  the  liberation  of  inhibitor  factors  which  affect
pregnancy  and  the  myometrium,  which sets off  an  active
process  through  uterine  stimulators.2 Different  substances
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intervene  during  labor,  like  prostaglandins  (PG),  estrogens
and  oxytocin,  among  others.
It  was  customary  to  follow  the  natural  evolution  of
labor  without  the application  of  any  method  to  acceler-
ate  it  (passive  handling  of labor),  either that  or  with  the
use  of  medications  which  accelerate  it (active  handling  of
labor).2
In  the  beginning  of  the 20th century,  in  1906,  the  first
uterotonic  was  discovered,  oxytocin.  It  was  not until  1911
when  its implementation  began  to  accelerate  labor.2 Oxy-
tocin  is a  cyclic  nonapeptide  obtained  through  chemical
synthesis.  Its  synthetic  form  is  identical  to that  of  a hormone
stored  in  the  posterior  hypophysis,  it stimulates  the smooth
muscle  of  the  uterine  strongly  toward  the  end  of  the preg-
nancy,  during  labor  and immediately  after  childbirth.  During
this  phase,  oxytocin  receptors  in the  myometrium  increase.
This  is  a  fast-acting  hormone,  with  a  latent  period  of  under
a  minute  after  intravenous  application  and  between  2  and
4  min  after  intramuscular  injection.3 In the  active  phase
of  the  first  period  of  labor,  oxytocin  is  commonly  used,  in
patients  who  require  it in  order  to  cause  uterine  contractions
and  to  regularize  its  frequency.4
In  some  countries,  in  addition  to  the  above,  other  medi-
cations  have  been  used  to  shorten  labor, such as  drotaverin
and  hyoscine  N-butylbromide  (BBH).4 This  is  part of a group
of  scopolamine  derivates,  which are muscarinic  antagonists
and  have  antispasmodic  effects.  It inhibits  cholinergic  activ-
ity  in  abdominal  and  pelvis  parasympathetic  lymph  nodes,
having  an  effect  on  the smooth  muscle  of  the  digestive
tract,  urinary,  biliary,  female  sexual  organ  and  especially
over  the  uterine--cervical  plexus,5 which  explains  its  effect
in  cervical  dilatation.  However,  this  has  not yet  been  clearly
stated.6
This  medication  does  not  have  effects  over uterine  con-
tractibility;  it does  not go through  the blood--brain  barrier
and  its  fixation  to  proteins  is  very  low,  with  a very  quick
distribution;  after intravenous  administration  the time  of
action  is around  10  min,  with  a peak  from  20  to  60  min  and  an
average  life  ranging  from  4 to  5 h.7 Its  main  way  of  excretion
is  renal.  No  adverse  effects  during  pregnancy  or  lactation
have  been  proven;  however,  its  use  is  recommended  with
caution  under  the first  trimester.  Side  effects  include:  dry
mouth,  facial  flushing,  intermittent  loss  of  accommodation
reflexes,  urinary  retention  and constipation.6
There  have  been  few  studies  in which  the  use  of  BBH
was  evaluated  to  shorten  labor.  These  have  reported  the
reduction  of labor  time  compared  to the  control  group  which
received  placebo,5 and  one  study  compared  its  effective-
ness  versus  oxytocin.8 The  objective  of  our study  was  to
compare  the  efficacy  and  safety  of BBH  versus  placebo  dur-
ing  labor.
Materials and methods
A randomized  experimental  study  was  designed  in which
patients  older than  18  years  were  included,  with  a  term
pregnancy  (37--42  weeks),  independent  from  the  parity with
cephalic  presentation,  with  a  clinically  adequate  pelvis  for
labor,  where  there  was  no  evidence  of macrosomia  (esti-
mated  fetal  weight  over 4000  g)  and  who  were  in the first
period  of  labor  in  the  active  phase  (dilatation  of  4 cm  or
more)  with  regular  uterine  activity  (3--4  contractions  in
10  min).  We  excluded  all  patients  who  needed  to  complete
childbirth  abdominally  due  to  different  causes.
Patients  who  were eligible  for  this  study  were  chosen  ran-
domly  to  receive  active  treatment  with  BBH versus  a  placebo
using  a sampling  of  two  proportions,  in an infinite  popula-
tion,  with  a potency  of 90%  to  detect  the  difference  of  30%
among  the  study  groups; a statistically  significant  level  of
0.05  was  established.  Over  these premises  a sample  size  of
40  patients  per  group  was  calculated.
The  study  included  a  total  of  86  women  who  met  the
inclusion  criteria  and  who  went  to  the Emergency  Service
of  the  ‘‘Dr.  José E.  González’’  University  Hospital  for  the
resolution  of  their  pregnancy  between  June  2009 and  July
2010.  All  patients  signed  an informed  consent.
The  patients  were  randomly  distributed  into  one of  the
two  groups: the  cases  group,  with  43  patients  who  were
administered  20  mg  of  BBH (diluted  in 9  ml  of  saline  solu-
tion)  intravenously  on  two  occasions  with  an  interval  of  1 h,
and  the  control  group  with  43  patients  who  were adminis-
tered  a placebo  (10  ml of  saline  solution)  at  a similar  dosage
and  interval.  After  every  dose, fetal  and maternal  car-
diac  frequency  monitoring  was  performed  and  patients  were
questioned  about side  effects.  Labor  progress  was  evalu-
ated  in a conventional  manner,  monitoring  the  time  of  every
period  of  labor,  in addition  to  the events  occurring  during  its
evolution  (spontaneous  rupture  of  membranes,  analgesia,
forceps  application,  etc.).  Also  weight  at birth,  Apgar  and
Capurro  were  evaluated.  Maternal  and  fetal  complications
were  evaluated  (uterine  atony,  vaginal  and perineal  tears,
etc.)  after  childbirth.  Central  tendency  measurements  were
utilized  and  the  duration  of every period  of labor  was  deter-
mined.
The  differences  between  groups  were  compared  with  2
or  Fisher’s  exact  test  in  the  case  of  categorical  variables  and
with  the Student’s  t-test  for continuous  variables.
Table  1  Comparison  of  the  characteristics  of  both  groups.
Placebo  BBH  p
Age  (years)  25.37  ±  6.98  25.65  ± 6.555  0.848
Nulliparous 13  (30.23%)  12  (27.9%)  0.499
Multiparous  30  (69.77%)  31  (72.1%)  0.499
Uterine fundus  (cm)  32.72  ±  1.821  32.581  ±  1.845  0.726
Estimated fetal  weight  (g)  3220.93  ±  255.004  3228.581  ±  217.226  0.881
Johnson method  (g)  3262.588  ±  294.40  3250.325  ±  292.241  0.847
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Table  2  Comparison  in labor  evolution.
Placebo  BBH  p
1st.  period  (min) 139.93  ± 92.484 151.186  ± 84.657  0.577
2nd. period  (min)  15.581  ± 9.334  13.186  ± 6.351  0.167
3rd. period  (min)  6.418  ± 3.265  6.581  ± 3.724  0.82
Table  3  Perinatal  results.
Placebo  BBH  p
Fetal  weight  (g)  3248.139  ± 374.837  3185.581  ± 397.28  0.454
Size (cm)  50.720  ± 1.992  50.767  ±  1.776  0.908
Silverman 0 (100%)  0  (100%)  0
Apgar 1  min  8.209  ±  0.666  8.209  ± 0.406  0
Apgar 5  min  9.186  ±  0.444  9  ±  0  0.007
Capurro (weeks)  39.146  ± 1.273  38.986  ±  1.180  0.547
Results
A  total  of  90  patients  were  included  in  the  study.  Of  these,
we  discarded  two  patients  from  the case  group  and two
from  the  control  group,  because  it became  necessary  for
them  to have  an  abdominal  birth.  The  cervical  conditions  of
the  placebo  group  upon  entry  were: dilation  of  5.6  ±  1.5  cm,
73  ± 11%  effacement  and  Bishop  Index  of  8.8  ±  1.2.  And  in
the  BBH  group  they  were:  dilation  of  5.2  ±  1.3  cm,  72  ±  11%
effacement  and  Bishop  Index  of  8.6  ± 1.2.  Upon  compari-
son  of  these  variables,  there  was  no  statistically  significant
difference,  which  indicates  that these  two  groups  were
homogenous  (Table  1).
Regarding  the  results  of the  duration  of  labor,  the first
period  of labor,  evaluated  in minutes,  was  139.93  ±  92.4  in
the  placebo  group  versus  151.186  ±  84.6  in the  BBH  group
(p  =  NS).  The  second  period  of  labor  had a duration  of
15.5  ±  9.33  min  in the first  group  and  13.18 ±  6.35  min in the
second  (p  =  NS).  Finally,  the third period  registered  a time  of
6.4  ± 3.2  min in the placebo  group  and 6.5  ±  3.7  min  in the
BBH  group.  We were  unable  to  find  a statistically  significant
difference  (Table 2).
Upon  separating  the groups  by  number  of  pregnancies,  we
found  that  the BBH group  had  a 159.1  ±  84  min  time  for the
first  phase  of  labor, with  significant  difference  of  p  =  0.002
compared  to  the control  group  (262.5  ±  92  min).
Concerning  the  perinatal  results,  we  observed  a fetal
weight  of 3248  ±  374  g,  a length  of  50.7  ±  1.9  cm  and
39.14  ±  1.2  Capurro  weeks  in the placebo  group,  and a
fetal  weight  of  3185.5  ±  397  g,  a  length  of  50.7  ±  1.7  cm
and  38.9  ±  1.1 Capurro  weeks  in the BBH group.  We  were
unable  to  find a statistically  significant  difference.  Concern-
ing  the  condition  of the babies  immediately  after birth,  we
reported  an Apgar  score  at  the first  minute  of  8.2  ±  0.6  and
9.1  ± 0.4  at  5 min  in  the control  group,  and  8.2  ±  0.4  at the
first  minute  and 9  ±  0  at 5 min  in the  BBH group.  We were
unable  to  find  a  statistically  significant  difference  (Table 3).
Discussion
Previous  studies  performed  with  BBH have reported  results
which  vary  from  no  difference  in cervical  dilation  time
to decreases  greater  than  2  h.  Aggarwal  et  al.7 performed
a  study  in which  they  found  that  in addition  to  a 35.6%
diminishment  in  the perception  of  pain  during  labor  due
to  the use  of  intravenous  BBH,  the  first  period  of  labor
was  reduced  in  a significant  way,  from  8 h  16  min in the
control  group,  to  3 h 46  min  in the BBH  group.  Samals
et  al. concluded  that  using  intravenous  BBH,  at  a dose of
20  mg,  was  able  to  diminish  the effort  of  labor  by  up  to
32%.9
Other  authors  recently  compared  the use  of  this  pharma-
ceutic  to  oxytocin  without  finding  a  statistically  significant
difference  in the effort  of  labor,10 which  is  the  reason  the
use  of  this  medication  should  be considered  as  an  option
for  primigravid  patients  which,  for  whatever  reason,  cannot
receive  oxytocin.
We  can  make  a recommendation  for  the  use  of  this  phar-
maceutic  in patients  with  the  results  obtained  by  separately
evaluating  groups  of  primigravid  and  multigravid  patients
which  received  BBH vs. a placebo;  with  regard  to  the  mul-
tiparous,  there  was  no  significant  difference  found  between
any  of  the  groups.
Just  like  in  other  studies,11 our results  show no  adverse
effects  on  the fetus,  which  were  evaluated  by  the APGAR  at
1  and  5  min.
Conclusions
Based on  the results  obtained  in  our investigation,  we can
conclude  that  although  we  were  not able  to  prove  a  sta-
tistically  significant  decrease  in the  effort  of  labor  in  both
groups,  we  did demonstrate  that  when the groups  of  prim-
igravidas  and multigravidas  are compared  separately,  the
primigravida  BBH group showed  a statistically  significant  dif-
ference,  with  a  p of  0.002.
Based  on  the  previous  studies,  we  can  make  a recom-
mendation  for  the use  of BBH in primigravid  patients,  also
demonstrating  that  the administration  of  this product  is safe
during  pregnancy,  since  there  were no  adverse  effects pre-
sented  during  its  administration,  or  among  the  babies in all
the  studied population.
Documento descargado de http://www.elsevier.es el 24-08-2016
Effect  of hyoscine  butylbromide  on  duration  of labor  33
Conflict  of interest
The  authors  have  no  conflicts  of  interest  to  declare.
Funding
No  financial  support  was  provided.
References
1.  Jyoti M, Singhal P, Choudhary D. Programmed labor. J  Obstet
Gynaecol India. 2006;56:53--5.
2. Cunningham FG, McDonald MD. Williams obstetrics. 20a Edición.
McGraw Hill. p. 243--292.
3. Sanborn BM, Dodge K,  Monga M, Qian A, Wang W,  Yue
C. Molecular mechanisms regulating the effects of oxytocin
on myometrial intercellular calcium. Adv Exp Med Biol.
1998;449:227--86.
4. Singh KC, Jain P, Goel N,  Saxena A. Drotaverine hydrochlo-
ride for augmentation of labor. Int J Gynaecol Obstet.
2004;84:17--22.
5. Sirohiwal D, Dahiya K, De M.  Efficacy of  hyoscine-N-butyl bro-
mide (Buscopan) suppositories as a  cervical spasmolytic agent
in labour. Aust N  Z J  Obstet Gynaecol. 2005;45:128--9.
6. Samuels LA, Christie L,  Roberts-Gittens B, Fletcher H, Frederick
J. The effect of hyoscine butylbromide on the first stage of
labour in term pregnancies. BJOG. 2007;114:1542--6.
7. Aggarwal P, Zutshi V,  Batra S. Role of hyoscine N-butyl bro-
mide (HBB, buscopan) as labor analgesic. Indian J  Med Sci.
2008;62:179--84.
8. Corsen G. A study of  the use and mode of  action of the antispas-
modic drug Buscopan in gynecology and obstetrics. Med Klin.
1983;48:1286--8.
9. Samal S,  Gupta U, Wable M. Buscopan (hyoscine-N-
butylbromide) in acceleration of labour. Indian Med Gaz.
1998;132:8--10.
10. Nobrega-Correa H, Guerra-Velasquez M, Reyna-Villasmil E,
Mejia-Montilla J,  et  al. Efectos del butil bromuro de hioscina-
oxitocina u oxitocina intravenosos en la duración del parto de
embarazos a término. Prog Obstet Ginecol. 2010;53:502--6.
11. Tewari K, Jabeen R, Sabzposh MA, Rabbani T. Comparison of
hyoscine-N-butylbromide and valethamate bromide in shorten-
ing the duration of  labour. Indian Med Gaz. 2003;137:15--9.
Documento descargado de http://www.elsevier.es el 24-08-2016
